Palogic Value Management’s Regenxbio RGNX Stock Holding History

Palogic Value Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$360K	Buy	30,040 +40	+0.1%	+$332	0.12%	161
2026 Q1	$251K	Buy	+30,000	New	+$315K	0.11%	160

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Palogic Value Management's RGNX Position: Q2 2026 in Review

Palogic Value Management increased its Regenxbio (RGNX) stake by 0.13% in Q2 2026, buying an estimated $332 and bringing the position to 30,040 shares worth $360K. The position accounts for 0.12% of the portfolio, ranked #161.

Palogic Value Management first reported a position in RGNX in Q1 2026 and has held it in 2 quarters since. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Palogic Value Management held 30,040 shares of Regenxbio worth $360K as of Q2 2026.
Palogic Value Management bought 40 Regenxbio shares in Q2 2026, an estimated $332.
Regenxbio made up 0.12% of Palogic Value Management's portfolio in Q2 2026, its #161 holding.
Palogic Value Management first reported a position in Regenxbio in Q1 2026 and has held it in 2 quarters since.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Palogic Value Management's 13F filing for Q2 2026, filed 14 Aug 2026.